Body
The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Among patients who had an out-of-hospital cardiac arrest, intravenous sodium nitrite given by paramedics during resuscitation did not significantly improve their chances of being admitted to or discharged from the hospital alive, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. Data also showed that patients taking rivaroxaban had higher rates of bleeding, but there was no excess in severe bleeding events such as intracranial or fatal bleeds.
For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
Three months after undergoing renal denervation (RDN)--a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity--patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
DUARTE, Calif. -- A City of Hope scientist is one step closer to discovering what weakens a pathogen that appears to cause babies to be born with abnormally small heads.
The Journal of the American Geriatrics Society (JAGS) this week rushed to publication a special article describing critical points for combatting the coronavirus disease (COVID-19) pandemic for older adults and those in long-term care.
The article offers a summary of current information and evidence, noting the imperative for understanding and acting upon the "ABCDs" of the COVID-19 crisis:
How to foster awareness of key clinical differences for older adults.
An experimental drug recently concluded a successful third-phase clinical trial and could potentially offer a new treatment for about 300,000 Canadians who have worsening chronic heart failure.
The VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) clinical trial examined the effects of a drug called vericiguat on patients at a high risk of death or hospitalization from heart failure.
New studies highlighting the chronic health burden of oversized breasts outline the long-term benefits of breast reduction surgery to health, levels of wellbeing, and quality of life.
The 12-year study compared feedback from more than 200 Australian women before and after having breast reduction surgery for the painful condition of breast hypertrophy - calling to task private and public health system funding for the surgery.
WASHINGTON--The international medical team that accomplished the world's first documented drone delivery of insulin for a patient living in a remote community described the project in an ENDO 2020 abstract that will be published in the Journal of the Endocrine Society.
Pathogenic fungi pose a huge and growing threat to global food security.
Currently, we protect our crops against fungal disease by spraying them with anti-fungal chemistries, also known as fungicides.
However, the growing threat of microbial resistance against these chemistries requires continuous development of new fungicides.
A consortium of researchers from the University of Exeter, led by Professor Gero Steinberg, combined their expertise to join the fight against plant pathogenic fungi.
Invasive procedures such as bypass surgery and stenting--commonly used to treat blocked arteries--are no better at reducing the risk for heart attack and death in patients with stable ischemic heart disease than medication and lifestyle changes alone. However, such procedures offer better symptom relief and quality of life for some patients with chest pain, according to two new, milestone studies.
Below please find link(s) to new coronavirus-related content published today in Annals of Internal Medicine. All coronavirus-related content published in Annals of Internal Medicine is free to the public. A complete collection is available at https://annals.org/aim/pages/coronavirus-content.
A War on Two Fronts: Cancer Care in the Time of COVID-19
What The Study Did: This study compared federal and foundation research funding for sickle cell disease and cystic fibrosis and investigated whether funding was associated with differences in drug development and research productivity.
Authors: John J. Strouse, M.D., Ph.D., of Duke University School of Medicine in Durham, North Carolina, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying heart conditions, according to a review published today in JAMA Cardiology by experts at The University of Texas Health Science Center at Houston (UTHealth).
Experts have known that viral illnesses such as COVID-19 can cause respiratory infections that may lead to lung damage and even death in severe cases. Less is known about the effects on the cardiovascular system.